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ABSTRACT
Background and Objectives: The cutaneous fentanyl patch is widely used to treat 
continuous pain in patients with cancer. Its use is hampered by a high inter- and 
intrapatient pharmacokinetic variability. Factors that influence this pharmacokinetic 
variability are largely unclear. The aim of these studies was to test if common 
patient variables, i) the use of the moderate CYP3A4 inhibitor aprepitant and ii) 
the localization of the fentanyl patch (upper arm versus thorax) influence systemic 
exposure to fentanyl in patients with cancer using a transdermal fentanyl patch.
Results: The AUC0–6 h of fentanyl was 7.1% (95% CI: –28% to +19%) lower 
if patients concurrently used aprepitant, compared to the period when patients 
used fentanyl only. The AUC0–4 h of fentanyl was 7.4% (95% CI: –22% to +49%) 
higher when the cutaneous fentanyl patch was applied to the upper arm compared 
to application at the thorax.
Conclusions: Neither the concurrent use of aprepitant, nor the localization of the 
fentanyl patch showed a statistically significant influence on fentanyl pharmacokinetics. 
Methods: We performed two prospective cross-over pharmacokinetic intervention 
studies. Both studies had two eight-day study periods. At day 8 of each study period 
blood samples were collected for pharmacokinetic analysis. In each study 14 evaluable 
patients were included.
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INTRODUCTION
Since decades the fentanyl cutaneous patch is used 
to treat chronic cancer pain [1]. The patch is widely used 
mainly because of its patient-friendly administration route 
[2, 3]. This patch is applied to the skin and has to be changed 
every 72 hours/3 days. Fentanyl is absorbed through the 
intact skin and forms a subcutaneous depot. Absorption is 
mediated by diffusion and is influenced by the thickness 
of the lipophilic keratinous stratus corneum [4, 5]. When 
fentanyl passes through the skin, fentanyl is absorbed into the 
microcirculation followed by the systemic circulation [1, 4].
A steady state is usually reached after application of 
a second transdermal fentanyl patch [6], although plasma 
concentration vary over the 72 hour period wherein a 
single patch is used [7]. Unfortunately, there is a wide 
intra- and interpatient pharmacokinetic variation in 
patients using fentanyl patches [7–11]. In clinical practice 
patients may already describe less painkilling effects of 
the cutaneous patch after 48 hours, and they may use 
extra opioids in the last 24 hours. Or they need to change 
their cutaneous patch every 48 hours leading to extra 
costs which are not always reimbursed by the insurers 
company. Despite the fact that numerous factors have been 
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investigated, this variation is still largely unexplained [8]. 
The area under the curve (AUC) of fentanyl increased 
up to 3-fold in volunteers who used strong CYP3A4 
inhibitors (like troleandomycine or ritanovir) together 
with fentanyl [12–16]. The combination of the moderate 
CYP3A4 inhibitor fluconazole and fentanyl showed a 
significant decrease in clearance of fentanyl [15]. 
Patients with cancer commonly require 
polypharmacy to treat side effects of (chemo-) therapy, 
complications of the underlying cancer or other diseases. 
Pharmacokinetic drug-drug interactions in cancer patients 
are therefore highly relevant [17, 18]. This is further 
emphasized by two case reports describing severe and even 
lethal fentanyl intoxications after a drug-drug interaction 
between fentanyl and fluconazole or itraconazole, 
respectively [19, 20]. Further study on the concurrent use 
of CYP3A4 inhibitors and fentanyl is therefore warranted. 
Aprepitant is deemed a moderate CYP3A4 inhibitor. It 
is the first neurokinin-1 (NK-1) receptor antagonist and 
it is used in combination with a 5-hydroxytryptamine-3 
(5HT3) antagonist and dexamethasone for the prevention 
of nausea and vomiting in case of highly or moderately 
emetogenic chemotherapy [21, 22]. Both aprepitant and 
fentanyl are thus widely and simultaneously used in 
cancer patients and because of aprepitant’s inhibitory 
capacity on CYP3A4, it could hypothetically increase 
the exposure of fentanyl, leading to more side effects 
like nausea or sleepiness. Nonetheless, higher systemic 
fentanyl concentrations could also lead to a better control 
of pain. Nevertheless, clinicians should always be aware 
of potential drug-drug interactions with fentanyl and more 
frequently monitor pain and side effects in these patients 
unexplained [8].
Another factor that may influence fentanyl exposure 
is the localization of the patch on the skin. Now, a fentanyl 
patch is advised to be applied on dry, intact, skin of the 
trunk, upper arm, or leg. Most patients prefer the upper 
arm. When changing the patch, it always has to be 
applied at another place because of the subcutaneous 
depot. However, also the localization where the fentanyl 
patch is applied may influence fentanyl absorption 
due to differences in skin thickness and/or the amount 
of subcutaneous fat. Two previous studies measured 
the residue in used patches of patients with cancer. 
Comparison of 100 patients showed a 7.5% lower delivery 
efficiency of fentanyl for patches applied to the leg in 
comparison to the arm [23]. The other study showed no 
differences in fentanyl absorption between patches applied 
to arm, shoulder, chest and back [11]. However, in both 
studies plasma fentanyl concentrations were not measured 
and both studies used inter patient comparisons, making 
the conclusions less robust given the high interpatient 
variation mentioned above.
We hypothesized that because fentanyl is highly 
lipophilic, higher plasma concentrations will be reached 
when the patch is used on areas with thicker skin, as 
they usually contain more fat. Mean skin thickness of 
the upper arm and the upper back are almost equal (43.9 
µm versus 43.4 µm),while the mean skin thickness of 
the thorax is less (37.6 µm) [24]. Therefore, we expected 
differences in fentanyl concentrations between the 
upper arm/ upper back and the ventral thorax region 
for sticking the fentanyl patch. For convenience of the 
patient we choose to compare the upper arm with thorax 
region for the transdermal delivery of fentanyl in the 
current study. 
In this report we describe the results of these two 
studies in which the effect of the concomitant use of 
aprepitant and the localization of the patch on the exposure 
to fentanyl were investigated. 
RESULTS
Aprepitant study
A total of 20 patients was included, while 6 patients 
were withdrawn from the study before start of PK 
sampling because of a deteriorated condition. As a result, 
14 patients (6 females and 8 males) with a median age 
of 61 years (IQR 55–71) completed the study and were 
evaluable. Unfortunately, two patients had missing PK 
measurements at the 6 hour time point. The demographic 
data of the evaluable patients are presented in Table 1. 
No significant differences were found in the 
chemistry results between period 1 and 2, and therefore 
did not affect the outcomes of the study.
The AUC0–6 h was 7.1% (95% CI: –28% ; +19%) 
lower when fentanyl was used in combination with 
aprepitant as compared to using fentanyl without 
aprepitant. The inter- and intra-patient coefficients of 
variation in fentanyl were 59% and 28%, respectively. Log-
transformed fentanyl concentrations are shown in Figure 1. 
AUC0–4 h analysis was also performed and showed the same 
non-significant results (relative difference in AUC0–4 h was 
4.5% (95% CI: –24%; +20%, fentanyl with aprepitant in 
comparison to fentanyl without aprepitant).
Patch localization study
Twenty-three patients were included. Fourteen 
patients (11 females and 3 males) with a median age of 62 
years (IQR 57–65) completed the study and were evaluable. 
The demographic information about these patients is 
presented in Table 2. The other nine patients were not 
evaluable due to clinical deterioration and missed blood 
sampling for pharmacokinetic analyses. The AUC was 7.4% 
(95% CI: –22% ± 49%) higher when the patch was applied 
to the upper arm as compared to the thorax. The inter- and 
intra-patient coefficient of variation in fentanyl (normalized 
AUC) were 48% and 41%, respectively Figure 2.
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DISCUSSION
The concomitant use of aprepitant for 3 days 
showed no statistically significant influence on the AUC 
of fentanyl in patients with cancer using transdermal 
fentanyl. Neither did the localization of the fentanyl 
patch. 
Several studies investigated drug-drug interactions 
with aprepitant before, because of its ability to inhibit 
CYP3A4 [25]. However only one study investigated 
drug-drug interactions with aprepitant and opioids [26]. 
Concomitant use of aprepitant and oxycodone in patients 
with cancer led to a 25% higher AUC of oxycodone [26]. 
Therefore, it is surprising that a drug like aprepitant, 
that is highly metabolized by CYP3A4 did not increase 
the exposure of fentanyl in a clinically and statistically 
significant extent. To limit the number of sampling 
moments in our patients, we have limited our study to 
Table 1: Patient characteristics in aprepitant study
N = 14
Sex, n
Male
Female
8
6
Age in years (median and IQR) 60.5 (55–71)
Height in cm (median and IQR) 172.5 (167–180)
Weight in kg (median and IQR) 71 (67–92)
BMI (median and IQR) 26 (19.5–29.5)
Fentanyl patch dose (μg/h) mean (range) 25 (12–43.5)
Laboratory results (n = 12)
(median (IQR) (normal range)
Creatinine (55–90 µL/min)
MDRD ( > 60 mL/min/1,73 m2)
AST ( < 31 U/L) (n = 11)
ALT ( < 34 U/L)
Bilirubin ( <17 umol/L)
ALP (< 98 U/L) (n = 11)
Period 1
67 (62–92)
87 (66–90)
30 (20–47)
23 (14–41)
7 (4–12)
133 (87–282)
Period 2
67 (61–86)
85 (70–90)
26 (21–45)
24 (12–40)
8 (4–12)
133 (90–247)
Figure 1: Plasma fentanyl concentrations (AUC0–6 h) aprepitant (right) versus no aprepitant (left).
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just 1 course aprepitant of 3 days. The effect of multiple 
courses would have been interesting.
Studies, as mentioned in the introduction, with 
strong CYP3A4 inhibitors did result in increased fentanyl 
exposure, although the effect sizes in those reports were 
smaller than theoratically expected [8, 12, 14, 16]. A 
previous study with fluconazole, a moderate CYP3A4 
inhibitor like aprepitant, showed a significantly lower 
clearance of fentanyl (11.6 ± 3 mL/min/kg vs 14.0 ± 2.5 mL/
min/kg) when used together, but no significant difference 
on AUC. In our study only AUC was measured, so possible 
effects on other pharmacokinetic parameters are unknown.
The most accepted hypothesis of fentanyl 
metabolism is that fentanyl is mainly metabolized in the 
liver by CYP3A4 mediated N-dealkylation resulting in 
the inactive metabolite norfentanyl [4, 27, 28]. However, 
a recent study showed that other unknown metabolic 
routes might also play a role in fentanyl metabolism and 
that the N-dealkylation step might be less predominant 
than previously thought [16], thereby possibly explaining 
the limited influence of aprepitant on fentanyl exposure. 
In that study, the metabolic clearance of fentanyl to 
norfentanyl was strongly inhibited by ketoconazole, but 
only a small increase of fentanyl exposure in general was 
seen [16]. For future research it would be interesting to 
study the different metabolites in plasma and urine to see 
whether aprepitant has an impact on the formation of those 
metabolites. 
Table 2: Patient characteristics in patch localization study
N = 14
Sex, n
Male
Female
3
11
Age, years 
(median and IQR) 62 (57–65)
Height, cm 
(median and IQR) 167 (162–172)
Weight, kg 
(median and IQR) 66 (63–78)
BMI
(median and IQR) 23.6 (22.6–28.0)
Fentanyl patch dose (μg/h) mean (range) 52.5 (12–175)
Figure 2: Plasma fentanyl concentrations (AUC0–4 h) upper arm vs thorax.
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We studied only the combination of aprepitant with 
transdermally applied fentanyl. Several rapid onset forms 
of fentanyl are now available, and we cannot exclude that 
there will be an effect of aprepitant on these formulations.. 
Previous studies with CYP3A4 inhibitors and fentanyl used 
mostly intravenously administrated fentanyl [14–16, 29, 30]. 
Of the rapid onset opioids only transmucosal fentanyl 
citrate has been studied [28]. The combination of the 
strong CYP3A4 inhibitor troleandomycine showed in both 
intravenously and transmucosally administrated fentanyl 
higher AUC’s compared to fentanyl alone [28, 29]. Since 
effect sizes of CYP3A inhibitors may be different among 
various administration routes, the results of the current 
analysis cannot be extrapolated to rapid onset opioids. 
Therefore, extra attention is needed when aprepitant is 
prescribed to patients who also use fentanyl rapid onset 
opioids .
In this study the localization of the fentanyl patch 
did not statistically significantly influence the exposure 
to fentanyl. An interpatient comparison in another study 
investigating fentanyl delivery, by analyzing patches, 
between patients applying patches to the leg versus the 
thorax found a small non-significant 7.5% difference 
in favor of the arm [23]. Our intra-patient comparison 
showed a similar (non-significant) difference between 
the arm and the upper thorax. Unfortunately, actual 
skin thickness or other characteristics describing skin 
condition were not measured in our study. Despite that, 
our study describes the situation in daily clinical care and 
is therefore of relevance for both patients and physicians. 
This study demonstrated that skin thickness is of minor 
importance for transdermally delivered fentanyl. 
The inter individual variation in plasma fentanyl 
levels were much larger than we had expected. Therefore 
our studies were underpowered to find a clinically and 
statistically significant difference of 30% in the AUC’s. 
CONCLUSIONS
In these two cross-over studies we could not identify 
any effect of aprepitant or the localization of the patch on 
fentanyl pharmacokinetics.
METHODS
The two studies were performed as single-center 
pharmacokinetic studies at the Erasmus MC Cancer 
Institute. Inclusion criteria were similar for the two studies: 
patients with cancer, age ≥ 18 years, using a stable dose 
of a transdermal fentanyl (Durogesic®) for at least 8 days 
irrespective of the dose used and given written informed 
consent. Exclusion criteria were: use of fentanyl rescue 
medication (other opioids were allowed), the use of strong 
CYP inhibitors or inducers [31] and evidence of serious 
psychiatric illness, confusion or intellectual disability.
Aprepitant study
This study used a randomized cross-over design 
with two study periods, each lasting eight days. In both 
periods patients used a stable dose of fentanyl, whereas 
patients were randomized for the use of aprepitant 
between arm A and arm B (Figure 3). Patients in arm A 
used aprepitant in the first study period, whereas patients 
in arm B used aprepitant in the second study period. 
Patients applied the patch alternately to the right and left 
upper arm, with a new patch on day one of each study 
period. The patch was changed every 3 days (72 hours), 
according to label instructions. Aprepitant was used in 
the order: 125 mg-80 mg-80 mg on day 6, 7 and 8 of the 
study period, respectively, concurrently with the fentanyl 
patch. Pharmacokinetic sampling was performed at day 
8, approximately 24 hours after changing a patch. Venous 
blood samples were taken at baseline (just before taking 
aprepitant) and at 2, 3, 4, 5 and 6 hours after administration 
of aprepitant or at similar times for the periods in which 
aprepitant was not used. Blood samples were collected in 
potassium EDTA coated tubes.
The following routine chemistry data were 
collected: aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), bilirubin, albumin and alkaline 
phosphatase (ALP), creatinine, estimated glomerular 
filtration rate (eGRF), calculated by Modification of Diet 
in Renal Disease (MDRD); formula: eGFR (mL/min/1.73 
m2) = 32788 × serum Creatinine (µmol/L) –1.154 × age 
(years) −0.203 × (0.742 when female) × (1.210 when of 
African descent).
Patch localization study
This study used a randomised cross-over design 
with two eight-day study periods as well. According to 
randomisation patients applied the patch to the upper 
arm (group A) or thorax (group B) first. The patch was 
changed every 3 days to the opposite arm or thorax, 
according to regular use. Pharmacokinetic sampling was 
performed at day 8, approximately 24 hours after changing 
a patch. Three venous blood samples were collected, with 
2 hours between each sample. After collection of the blood 
samples patients switched to the other patch localization, 
either thorax or upper arm dependent on randomization. 
The same sampling procedure as during the first study 
period was followed. 
Measurements of fentanyl plasma concentrations
We quantified fentanyl in EDTA plasma. A validated 
UPLC-MS/MS method. This method consisted of a 
Waters Acquity UPLC sample manager, coupled to a triple 
quadruple mass spectrometer operating in the multiple 
reaction monitoring mode (MRM) with positive ion electro 
spray ionization (Waters, Etten-Leur, The Netherlands). 
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The multiple reaction monitoring transitions was set at 
337→188.
Chromatographic separations for fentanyl were 
achieved on an Acquity UPLC® BEH C18 1.7 µm 2.1 × 
100 mm column eluted at a flow-rate of 0.350 mL/min 
on a gradient of methanol. A cycle time for this method 
was about 6 minutes. Calibration curves were linear 
over a wide range (0.100 to 10.0 ng/mL) with at lower 
limit of quantitation (LLQ) of 0.100 ng/mL for fentanyl. 
The within and between-run precisions, including the 
LLQ, were ≤ 5.52 % and ≤ 6.12 %, respectively, while 
the average accuracy ranged from 86.2 % to 97.5%. The 
extraction of 200 µL of plasma involved a deproteinization 
step with acetone, followed by a simple liquid extraction 
with ethyl acetate. The organic phase was evaporated and 
subsequently dissolved in 100 µL methanolic solutions, 
from which aliquots of 10 µL were injected into the UPLC-
MS/MS system.
Statistics
For both studies (1. the combination of aprepitant 
and 2. the localization of the fentanyl patch) a difference 
in systemic exposure to fentanyl of 30% was determined to 
Figure 3: Study design of both the aprepitant study (upper scheme) and patch localization study (bottom scheme).
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be clinically relevant. It was assumed that the intra-patient 
relative standard deviation in fentanyl pharmacokinetics was 
20%. Given a power of 80%, 14 patients were required in 
each study to detect a difference. For the primary endpoint, 
the following analysis approach was taken. A natural log 
transformation was applied to the AUC0–4 h and AUC0–6 
h values in order to normalize the distributions [4, 7, 32]. 
Estimates for the mean differences in (log) AUCs were 
obtained using a linear mixed effect model with treatment, 
sequence and period as fixed effects and subject within 
sequence as a random effect [33]. Variance components 
were estimated based on restricted maximum likelihood 
(REML) methods and the Kenward-Roger method of 
computing the denominator degrees of freedom was used. 
The mean differences and 95% CIs for the differences 
were exponentiated to provide point estimates of the ratio 
of geometric means and 95% CIs for these ratios, which 
can be interpreted as relative differences in percentages. 
Regular chemistry results, which were measured only in the 
aprepitant study, were compared between periods by means 
of the Wilcoxon signed rank test.
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